While social media can be a tool for pharma to help educate the public, it has also become a forum for the public to express their views about pharma, and it's not always flattering, as evidenced by the recent antivaccine movement.
Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs
Sales of the new cancer drug topped expectations since its February launch.
Study finds vaccines still not linked to autism; investments in healthcare start-ups hit record high this year; biosimilars are already bearing down on prices overseas
Celltrion expects its Remicade biosimilar to hit the US this year; Vivus cuts its sales force; BMJ accuses Novartis of interfering with clinical trials
FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.
Achillion's experimental HCV drug cleared the virus in six weeks when combined with Gilead's Sovaldi; Sanofi will replace a third of its sales managers; GSK shutters Montana vaccine R&D.
Measles outbreak news aside, doctors need help identifying illnesses vaccines have made uncommon.
Pfizer ends spinal muscular atrophy collaboration; abuse-deterrent Zohydro scores approval; measles outbreak at Disneyland linked to 36 cases.
FDA has approved Novartis's Bexsero after approving Pfizer's Trumemba this past October.
FDA draws fine line between health and wellness apps; Colorado gives biosimilar swap law another look; ZMapp is set to start human trials of its Ebola vaccine.
The $509-million agreement gives J&J rights to AC Immune's experimental anti-Tau vaccine.
The artwork is meant to inspire debate and donations for vaccinations.
Pfizer continues to scoop up vaccine assets, Dendreon heads to auction with no lead bidder, Genentech and 23andMe will take on the Parkinson's genome.
The Herpes zoster vaccine candidate showed relatively strong efficacy in a Phase-III trial, but its dosing is less convenient than an older product sold by rival Merck.
Pfizer has kicked off a disease-awareness campaign, "Take Action Against Meningitis," urging parents to discuss vaccinations with their healthcare providers with paralympic snowboarder Amy Purdy.
GSK is set to announce US job cuts this week, sales reps are getting the axe in China, and the FDA has rejected Avanir's inhalable migraine medication.
Canada's National Microbiology Laboratory developed the vaccine, which has been licensed to NewLink Genetics Corp.
Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.
It could also eat into Merck's Pneumovax sales.
A greenlight could garner Pfizer $1B in sales.
The meningitis and encephalitis medications earned a combined $300 million last year.
A study shows that veering off the recommended vaccination schedule ups the risk for childhood seizures.
The CDC said Thursday that most of the 288 recent US measles cases were caused by un-vaccinated travelers who brought the virus home with them.
The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.
The Las Vegas twosome give the anti-vaccination movement their signature treatment.
Researchers find public service announcements and physician information don't change minds, but a California practice found one way it could.
Pfizer hit its endpoints for preventing pneumonia among the elderly, but the data may not be robust enough to spur vaccination.
Queensland, Australia, researchers find the risk of high-grade cervical abnormalities fell 46% among women who had received all three doses of the HPV vaccine.
Ten percent of surveyed doctors told the Centers for Disease Control that reimbursement rates are not enough.
Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.